August 24, 2018
This letter to TPSAC summarizes the UCSF TCORS' public comments to FDA on the RJR application to FDA to be allowed to market Camel Snus as less dangerous. The tracking number in regulations.gov is 1k2-9510-dtqo. A PDF of the letter (including all the individual comments) is available here.
August 23, 2018
Tobacco Products Scientific Advisory Committee
August 24, 2018
My colleagues and I at UCSF have submitted this public comment to FDA on RJR's application to market Camel Snus as less dangerous. The tracking number on regulations.gov is 1k2-9510-3515. A PDF of the comment is here.
Docket Number: FDA-2017-N-4678-0001
Clinical Trials and Observational Epidemiology Indicate that Allowing Snus to be Marketed with Modified Risk Claims is Unlikely to Confer Population Benefit and May Cause Harm by Depressing Smoking Cessation
August 24, 2018
My colleagues at UCSF have submitted this public comment to FDA regarding RJR's application to sell Camel Snus as a reduced risk product. The tracking number at regulations.gov is 1k2-9510-3zjn. A PDF of the comment is here.
Docket number: FDA-2017-N-4678-0001
Reynolds’ own data do not support their claim that because exclusive users of Camel Snus experience lower levels of exposure to some toxicants, they will reduce their risk of harm from lung cancer, oral cancer, respiratory disease, and heart disease
August 24, 2018
Bonnie Halpern Felsher from Stanford, in collaboration with colleagues at UCSF submitted this comment to FDA on RJR's application to market Camel Snus as a less dangerous product. The tracking number on regulations.gov is 1k2-9510-ujes. A PDF of the comment is available here.
Docket Number: FDA-2017-N-4678-0001